The specific condition cited is non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a relatively common cause of sudden, painless vision loss, which can lead to permanent impairment of sight in some cases. Medically, it is caused by decreased blood flow to the front part of the optic nerve, though the precise underlying causes of the condition remain not completely understood.
The FDA’s decision follows an evaluation of multiple data sources, including clinical trial data, animal studies, and post-marketing data such as observational studies and individual case reports. The agency stated that the drug safety communication applies to all medicines with GLP-1 RA activity and does not reference findings specific to any single manufacturer’s products.
Importantly, the FDA’s action distinguishes between association and established causation. While the regulator is requiring the addition of information to the “warnings and precautions” section of drug labels, both major manufacturers maintain that the current data do not definitively establish a cause-and-effect relationship.
“FDA’s drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines. We are carefully evaluating the update and will respond to FDA promptly,” a spokesperson for Eli Lilly said in a statement.
Novo Nordisk took a similar stance, emphasizing the overall safety profile of its drugs. “Novo continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines,” a company spokesperson stated.
The regulatory landscape for this side effect has evolved over the past year. Last year, the European Medicines Agency (EMA)’s safety committee indicated that NAION may affect up to 1 in 10,000 people taking semaglutide—the active ingredient in Wegovy, Ozempic, and Rybelsus—for at least one year. That assessment marked the first time a major regulator had confirmed the side effect in connection with these drugs.
The potential risk has also had tangible consequences for patients in Europe. Reports indicate that four patients in Denmark who experienced vision loss after using Novo’s GLP-1 drugs were granted compensation by the Danish Patient Compensation scheme last year.
Recent scientific literature provides further context to the FDA’s decision. A large study published in 2025 tracked nearly 175,000 diabetic patients treated with semaglutide and compared them to an equal number of patients taking non-GLP-1 medications. The research found that the risk of NAION more than doubled after two years of treatment with a GLP-1 drug compared to diabetes medicines from other classes. However, it is crucial to note that observational studies like this can identify associations but cannot prove that the medication directly caused the condition, as other factors may contribute to the risk.
Market analysts suggest that the regulatory action may not significantly alter prescribing habits due to the rarity of the condition relative to the drugs’ therapeutic benefits. “The FDA action may temporarily increase patient and investor concern, but the rarity of NAION and substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits should preserve a favorable benefit-risk profile and limit changes to prescribing,” said Citi analyst Geoff Meacham.
For patients currently on these medications, the FDA’s update serves as an alert to healthcare providers to remain vigilant for symptoms of vision loss. It does not constitute a ban or a recommendation to stop treatment, but rather a requirement for clearer communication of potential risks. Patients experiencing sudden vision changes should consult their healthcare provider immediately. The distinction between the substantial benefits of GLP-1 RAs for weight management and diabetes control and the rare risk of NAION remains the central focus of ongoing medical review.
